arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

Scinai Immunotherapeutics Ltd.

SCNI

$0.24 ▼ -0.01 (-3.38%) at close

7 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Scinai Immunotherapeutics Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.2B

Dividend Yield —

Revenue Growth 99.2%

Op. Margin —

ROIC -73.5% ↘

FCF / Share $-0.00 ↗

Trailing P/E —

Price / Book 410.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.31M

↑ +99.2% —

Net Income Profit after all expenses

$-8.31M

↓ -273.2% —

FCF / Share Free cash flow per share

$-0.00

↑ +67.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2017 20-F ↗
Revenue Growth YoY (%)	99.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1141%)	—	—	—	—	—	—
EPS Growth YoY (%)	—	—	60.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	50.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	N/M	N/M	-12.1% Weak ↑ Weak Improving Year-over-year change in net income	29.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-492.1% Weak Weak Year-over-year change in net income	86.1% Excellent Excellent Year-over-year change in net income	—
FCF Growth YoY (%)	67.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	69.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	40.3% Excellent Excellent Year-over-year change in free cash flow	19.8% Good Good Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2017 20-F ↗
FCF Margin (%) (%)	-461.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—
FCF / Net Income (x)	0.73x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-1.32x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.54x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.40x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2017 20-F ↗
Return on Invested Capital (%)	-73.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-68.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-167.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	496.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-873.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-64.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-64.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	55.6% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	-40.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-33.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-102.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-783%)	48.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+220%)	142.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+848%)	—	—	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2017 20-F ↗
Debt to Equity (x)	—	—	—	-0.22x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-136%)	0.38x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-36%)	—	—
Interest Coverage (x)	—	-60.41x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	28.30x Excellent Excellent Operating income divided by interest expense Optimal: > 5x	-12.08x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-1.66M	$-1.96M	$-4.87M	$-13.69M	$-17.00M	—	—
Debt / EBITDA (x)	—	—	—	-0.04x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.04x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2017 20-F ↗
Revenue per Share (USD)	$0.00	$0.00	—	—	—	—	—
Basic EPS, GAAP (USD)	—	—	$-0.00	$-0.01	$-0.02	—	—
Free Cash Flow per Share (USD)	$-0.00	$-0.00	$-0.01	$-0.01	$-0.01	—	—
Book Value per Share (USD)	$0.00	$0.00	$-0.00	$-0.00	$0.00	—	—
Tangible Book Value per Share (USD)	$0.00	$0.00	$-0.00	$-0.00	$0.00	—	—
Basic Weighted Avg Shares (shares)	9.34B	3.23B	1.56B	754.08M	564.58M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2017 20-F ↗
Working Capital (USD)	$469.00K	$585.00K	$3.67M	$12.03M	$15.40M	—	—
Total Equity (USD)	$8.10M	$9.98M	$-4.57M	$-1.76M	$982.00K	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2017 20-F ↗
Sales/Revenue/Turnover (USD)	$1.31M	$658.00K	—	—	—	—	—
Depreciation Expense (USD)	$1.42M	$1.65M	$514.00K	$562.00K	$471.00K	—	—
Net Income, GAAP (USD)	$-8.31M	$4.80M	$-6.50M	$-5.80M	$-8.21M	$-1.39M	$-9.97M
Operating Cash Flow (USD)	$-6.03M	$-6.33M	$-9.38M	$-7.26M	$-7.43M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 9 quarters

Scinai Immunotherapeutics Ltd.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare SCNI with peers